Tambor, Ellen http://orcid.org/0000-0003-4779-5552
Robinson, Matoya
Hsu, Lewis
Chang, Hsing-Yuan
Al Naber, Jennifer
,
Funding for this research was provided by:
Doris Duke Charitable Foundation (2019104)
Cyclerion Therapeutics
Global Blood Therapeutics
CSL Behring
Novartis Pharmaceuticals Corporation
Roche
Sanofi
Article History
Received: 27 April 2021
Accepted: 24 September 2021
First Online: 19 October 2021
Declarations
:
: The study protocol was reviewed by Advarra and received an exempt determination. Using the Department of Health and Human Services regulations found at 45 CFR 46.104(d)(2), the IRB determined that the project is exempt from IRB oversight. The IRB also completed the necessary additional limited review considerations as set forth under the Revised Common Rule, 45 CFR 46.104(d).
: Not applicable.
: The authors declare that they have no competing interests.